Cite
LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial.
MLA
Qin, S., et al. “LBA35 Camrelizumab (C) plus Rivoceranib (R) vs. Sorafenib (S) as First-Line Therapy for Unresectable Hepatocellular Carcinoma (UHCC): A Randomized, Phase III Trial.” Annals of Oncology, vol. 33, Sept. 2022, pp. S1401–02. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.08.032.
APA
Qin, S., Chan, L. S., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Sultanbaev, A. V., Pazgan-Simon, M., Pisetska, M., Liang, X., Chen, C., Nie, Z., Wang, L., Cheng, A.-L., Kaseb, A., & Vogel, A. (2022). LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial. Annals of Oncology, 33, S1401–S1402. https://doi.org/10.1016/j.annonc.2022.08.032
Chicago
Qin, S., L.S. Chan, S. Gu, Y. Bai, Z. Ren, X. Lin, Z. Chen, et al. 2022. “LBA35 Camrelizumab (C) plus Rivoceranib (R) vs. Sorafenib (S) as First-Line Therapy for Unresectable Hepatocellular Carcinoma (UHCC): A Randomized, Phase III Trial.” Annals of Oncology 33 (September): S1401–2. doi:10.1016/j.annonc.2022.08.032.